Work

At the intersection of endomyocardial biopsy and dd-cfDNA, where do we go?

Year: 2026

Type: review

Abstract: Cardiac allograft rejection has traditionally been assessed by endomyocardial biopsy (EMB). Blood-based assays such as donor-derived cell-free DNA (dd-cfDNA) are increasingly used, yet emerging data highlight discordance between these approaches. This review evaluates recent data, examines causes of disagreement, and suggests strategies to better align EMB and dd-cfDNA.

Source: Cardiovascular Pathology

DOI: 10.1016/j.carpath.2026.107825

Authors: Gregory A. Fishbein, Marc K. Halushka

Institutions: University of California, Los Angeles, Cleveland Clinic, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University

Language: English

Topic: Transplantation: Methods and Outcomes

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,210